U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H5O3.C5H14NO
Molecular Weight 241.284
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHOLINE SALICYLATE

SMILES

c1ccc(c(c1)C(=O)O)[O-].C[N+](C)(C)CCO

InChI

InChIKey=UDKCHVLMFQVBAA-UHFFFAOYSA-M
InChI=1S/C7H6O3.C5H14NO/c8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7/h1-4,8H,(H,9,10);7H,4-5H2,1-3H3/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C7H6O3
Molecular Weight 138.121
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C5H13NO
Molecular Weight 103.163
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1203465600000
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1203465600000
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1203465600000
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1203465600000
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1355011200000
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1355011200000
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1355011200000
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
238 min
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SALICYLIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
Health Status: unhealthy
Age Group: 23.05 ± 5.7 years
Sex: M+F
Sources:
Other AEs: Redness, Scales...
Other AEs:
Redness
Scales
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
Health Status: unhealthy
Age Group: 23.05 ± 5.7 years
Sex: M+F
Sources:
Scales
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
Health Status: unhealthy
Age Group: 23.05 ± 5.7 years
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
major
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE).
1999 May
Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis.
1999 Sep
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
2001
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.
2001
Hydroxyl radical adduct of 5-aminosalicylic acid: a potential marker of ozone-induced oxidative stress.
2001
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059.
2001 Apr
Cyanide-resistant alternative respiration is strictly correlated to intracellular peroxide levels in Acremonium chrysogenum.
2001 Apr
[Principal constituents from flowering aerial parts of wild pansy].
2001 Apr
A novel jasmonic acid-inducible rice myb gene associates with fungal infection and host cell death.
2001 Apr
Abnormal callose response phenotype and hypersusceptibility to Peronospoara parasitica in defence-compromised arabidopsis nim1-1 and salicylate hydroxylase-expressing plants.
2001 Apr
Evaluation of insulin permeability and effects of absorption enhancers on its permeability by an in vitro pulmonary epithelial system using Xenopus pulmonary membrane.
2001 Apr
Uptake mechanism of valproic acid in human placental choriocarcinoma cell line (BeWo).
2001 Apr 13
Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease.
2001 Apr 17
Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on nitric oxide-induced hydroxyl radical generation in the rat heart.
2001 Apr 30
[Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
2001 Apr 6
Hereditary palmoplantar keratoderma (four cases in three generations).
2001 Feb
Isolation and preliminary characterization of the medium-chain fatty acid:CoA ligase responsible for activation of short- and medium-chain fatty acids in colonic mucosa from swine.
2001 Feb
Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis.
2001 Feb
Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction.
2001 Feb
3-Hydroxybenzoic acid as an internal standard for the high-pressure liquid chromatography quantitation of salicylic acid in plants.
2001 Feb 1
Molecular cloning of the nahG gene encoding salicylate hydroxylase from Pseudomonas fluorescens.
2001 Feb 28
Probenazole induces systemic acquired resistance in Arabidopsis with a novel type of action.
2001 Jan
Guidelines for the management of cutaneous warts.
2001 Jan
Ion channel-forming alamethicin is a potent elicitor of volatile biosynthesis and tendril coiling. Cross talk between jasmonate and salicylate signaling in lima bean.
2001 Jan
Free and conjugated benzoic acid in tobacco plants and cell cultures. Induced accumulation upon elicitation of defense responses and role as salicylic acid precursors.
2001 Jan
Cause of high variability in drug dissolution testing and its impact on setting tolerances.
2001 Jan
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.
2001 Jan 15
Characterization of a rice (Oryza sativa L.) Bowman-Birk proteinase inhibitor: tightly light regulated induction in response to cut, jasmonic acid, ethylene and protein phosphatase 2A inhibitors.
2001 Jan 24
Release of salicylic acid, diclofenac acid and diclofenac acid salts from isotropic and anisotropic nonionic surfactant systems across rat skin.
2001 Jan 5
Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells.
2001 Jan-Feb
Interaction of the Arabidopsis receptor protein kinase Wak1 with a glycine-rich protein, AtGRP-3.
2001 Jul 13
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus.
2001 Jul 6
Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts.
2001 Jun 1
A recessive mutation in the Arabidopsis SSI2 gene confers SA- and NPR1-independent expression of PR genes and resistance against bacterial and oomycete pathogens.
2001 Mar
Signaling mediated by the closely related mammalian Rho family GTPases TC10 and Cdc42 suggests distinct functional pathways.
2001 Mar
Development of QSARs to investigate the bacterial toxicity and biotransformation potential of aromatic heterocylic compounds.
2001 Mar
Interference by bilirubin in salicylate measurement.
2001 Mar
Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs.
2001 Mar
In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis.
2001 Mar 1
Microdialysis of salicylic acid from viscous emulsion samples prior to high-performance liquid chromatographic determination.
2001 Mar 30
Determination of salicylate, gentisic acid and salicyluric acid in human urine by capillary electrophoresis with laser-induced fluorescence detection.
2001 Mar 5
Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals.
2001 May
Asbestos causes apoptosis in alveolar epithelial cells: role of iron-induced free radicals.
2001 May
Acanthoamoeba attachment to contact lenses.
2001 May
Anti-inflammatory and antipyretic effects of Trigonella foenum-graecum leaves extract in the rat.
2001 May
Measurement of free radical production by in vivo microdialysis during ischemia/reperfusion injury to skeletal muscle.
2001 May 1
Laryngeal oedema caused by accidental ingestion of Oil of Wintergreen.
2001 May 11
6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum.
2001 May 8
Patents

Sample Use Guides

The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.
Route of Administration: Topical
In Vitro Use Guide
Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:35:58 UTC 2021
Edited
by admin
on Sat Jun 26 02:35:58 UTC 2021
Record UNII
KD510K1IQW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHOLINE SALICYLATE
INN   JAN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
CHOLINE SALICYLATE [VANDF]
Common Name English
BENZOIC ACID, 2-HYDROXY-, ION(1-), 2-HYDROXY-N,N,N-TRIMETHYLETHANAMINIUM
Common Name English
(2-HYDROXYETHYL)TRIMETHYL AMMONIUM SALICYLATE
Systematic Name English
CHOLINE SALICYLATE [WHO-DD]
Common Name English
CHOLINE SALICYLATE [MI]
Common Name English
CHOLINE SUBSALICYLATE
Common Name English
SALICYLIC ACID, ION(1-), CHOLINE
Common Name English
CHOLINE SALICYLATE [USAN]
Common Name English
CHOLINE SALICYLATE [MART.]
Common Name English
SALICYLIC ACID CHOLINE SALT
Common Name English
(2-HYDROXYETHYL)TRIMETHYLAMMONIUM 2-HYDROXYBENZOATE
Systematic Name English
CHOLINE SALICYLIC ACID SALT
Common Name English
CHOLINE, SALICYLATE (SALT)
Common Name English
ETHANAMINIUM, 2-HYDROXY-N,N,N-TRIMETHYL-, 2-HYDROXYBENZOATE (1:1)
Systematic Name English
CHOLINE SALICYLATE [JAN]
Common Name English
CHOLINE SALICYLATE [INN]
Common Name English
ETHANAMINIUM, 2-HYDROXY-N,N,N-TRIMETHYL-, SALT WITH 2-HYDROXYBENZOIC ACID (1:1)
Common Name English
Classification Tree Code System Code
WHO-ATC N02BA03
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
WHO-VATC QN02BA03
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
NCI_THESAURUS C257
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
Code System Code Type Description
EVMPD
SUB06219MIG
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY
DRUG BANK
DB14006
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY
CAS
2016-36-6
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY
ECHA (EC/EINECS)
217-948-8
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY
EPA CompTox
2016-36-6
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY
NCI_THESAURUS
C76798
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY
MERCK INDEX
M3483
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL2104095
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY
PUBCHEM
54686350
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY
RXCUI
20974
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY RxNorm
INN
1938
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY
MESH
C015075
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY
FDA UNII
KD510K1IQW
Created by admin on Sat Jun 26 02:35:59 UTC 2021 , Edited by admin on Sat Jun 26 02:35:59 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY